Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK Viremia: Kinase Inhibition to Decrease Nephropathy Intervention Trial
ISRCTN40228609Phase 3Completed
- Sponsor
- University of Calgary
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus and leflunomide in BK polyomavirus infection and BK polyomavirus associated nephropathy (BKPyVAN), sponsored by University of Calgary. Primary endpoint: Multiple failure times per subject. Started Mar 2010; status: completed.
02
Drugs
sirolimusleflunomide
03
Conditions
BK polyomavirus infectionBK polyomavirus associated nephropathy (BKPyVAN)
Beyond the preview
Go deeper on ISRCTN40228609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40228609.